WARREN, N.J., April 24, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences:
Bank of America Securities 2025 Health Care Conference
Tuesday, May 13 at 10:00 a.m. PT / 1:00 p.m. ET
RBC Capital Markets Global Healthcare Conference 2025
Tuesday, May 20 at 2:05 p.m. ET
William Blair 45th Annual Growth Stock Conference 2025
Tuesday, June 3 at 9:20 a.m. CT / 10:20 a.m. ET
Goldman Sachs 46th Annual Global Healthcare Conference 2025
Tuesday, June 10 at 9:20 a.m. ET
The presentations will be webcast live on the Events and Presentations page under the Investor section of PTC Therapeutics' website at https://ir.ptcbio.com/events-presentations and will be archived for 30 days following the presentation. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection.
About PTC Therapeutics, Inc.
PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. The company's strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, X, and LinkedIn.
For More Information:
Investors:
Ellen Cavaleri
+1 (615) 618-6228
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Jeanine Clemente
+1 (908) 912-9406
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$86.00 |
| Daily Volume: | 0 |
| Market Cap: | US$6.900B |
November 04, 2025 August 07, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
